

Respiratory Viruses in Luxembourg (ReViLux)

Sentinel Network Report - Week 04

Summary

At the end of week 2024/04, rates of influenza-like illness remained elevated and the sentinel network detected a medium epidemic activity, based on 11.9% of consultations being associated with influenza-like illness. Out of the specimens collected by the sentinel network over the last week, the percentage of positive tests for Influenza virus A was 40.6%, 6.2% for RSV and 3.1% for SARS-CoV-2.

Influenza A positivity rates maintained at above 40% for the last two weeks (2024/03 and 2024/04), with 87.6% characterised as A(H1)pdm09 viruses and 12.4% as H3. 50% of the characterised A(H1)pdm09 viruses (N=26) were part of the A/Sydney/5/2021 clade and remaining 50% belonged to A/Victoria/4897/2022 clade. All of the A(H3) characterized viruses (N=4) were part of the were part of the A/Thailand/8/2022 clade.

Positivity of SARS-CoV-2 decreased from 13.1% in week 2024/01 to 3.1% in week 2024/04. Regarding SARS-CoV-2 genomics within sentinel samples, from week 2023/40 to week 2023/44, XBB.1.9 and EG.5, a sub-variant of XBB.1.9, were responsible for the highest number of infections, but since week 2023/47 JN.1 a sub-variant of BA.2.86, has been dominant in Luxembourg.

Sentinel Surveillance Network

The Sentinel Surveillance aims at monitoring the circulating respiratory viruses, from traditional ones like Influenza to more recent ones like SARS-CoV-2, and hence underpin public health actions. The Sentinel Network is a group of general practitioners and paediatricians spread across the country. They report the weekly number of patients showing symptoms suggestive of acute respiratory infection (ARI) and influenza-like illness (ILI), and those patients are then sampled and tested for a panel of respiratory viruses. The circulation of respiratory viruses in the north hemisphere is generally monitored by seasons that go from week 40 to week 20. The period between weeks 20 and 40 is usually called inter-season.

Clinical results

Last week (2024/04), 11.9% of the consultations were reported as ILI, representing a medium epidemic activity for Luxembourg, according to ECDC and the Moving Epidemic Method. Since week 2023/51 reported rates were between medium/high levels. Of note, only a few surgeries participated due to holiday season and therefore, results for week 2024/01 are not presented. The history of ILI consultations is displayed in Figure 1, and a detailed summary of the number of ARI and ILI cases during the last four weeks is included in Table 1.

Laboratory results

Over the last week, the most frequently detected viruses (according to positivity rates) were Influenza virus A (40.6%), followed by Human rhinovirus (16.0) and Adenovirus (7.4%). Positivity rates of Influenza A decreased from 35.3% (2023/52) to 22.5% (2024/02), but rates nearly doubled to 43.3% in week 2024/03 and remained above 40% in week 2024/04. 130 of 204 (63.7%) samples have been further characterized with 87.6% as A (H1)pdm09 and 12.3% as A (H3). 30 samples from the sentinel network were genetically characterised with 13 (H1) samples reported as clade 5a.2a (A/Sydney/5/2021), 13 (H1) samples as subclade 5a.2a.1 (A/Victoria/4897/2022) and 4 (H3) samples as clade 2a.3a.1 (A/Thailand/8/2022). All of the genetically characterised clades belong to clades of the recommended vaccine components.

Over the last three weeks low Influenza B circulation was detected.

Test positivity for RSV decreased from 28.5% (2023/51) to 2.3% (2024/02), but increased slightly to 6.4% (2023/04). Of note, not all samples from week 2024/03 have been tested yet, and results will be displayed next week. Overall, this season (23/24), the highest impact of RSV was seen among the 0-4 years age group (Figure 3). To date, 149 RSV detections were further subtyped as either RSV A (N=129, 86.5%) or RSV B (N=20, 13.4%).

Positivity of SARS-CoV-2 decreased over the past 4 weeks from 13.1% in week 2024/01 to 3.1% in week 2024/04. Hundred seventeen of 210 SARS-CoV-2 detections (56%) have been

further genetically characterised. From week 2023/40 to week 2023/44, XBB.1.9 and EG.5, a sub-variant of XBB.1.9, were responsible for the highest number of infections, but since week 2023/47 JN.1 a sub-variant of BA.2.86, has been dominant in Luxembourg (Figure 4).

An overview of the circulating viral pathogens during the current and previous inter- season is displayed in Figure 2 and Table 2.





Figure 1. Percentage of patients with influenza-like illness over the last three seasons Background colours according to intensity of circulation: baseline, low, medium, high, very high. Data from 2024/01 not presented as low return

Week	ARI		_	ILI	Total
	Ν	%	N	%	consultations
2023/52	28	34.15	11	13.41	82
2024/02	34	13.77	31	12.55	247
2024/03	60	18.63	28	8.70	322
2024/04	79	18.76	50	11.88	421

Table 1. Syndromic surveillance over the last 4 weeks

ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness. Data from 2024/01 not presented as low return



Circulation of common viral respiratory pathogens 2023/24 Sentinel network


Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by calendar week. Results from last weeks are not yet consolidated. FLU-A: influenzavirus A; FLU-B: influenzavirus B; PIV: parainfluenzavirus; RSV: respiratory syncytial virus; ADV: adenovirus; MPV: metapneumovirus; HRV: human rhinovirus; SC2: SARS-CoV-2.

National Reference Laboratory for Acute Respiratory Infections Department of Microbiology - Laboratoire national de santé 1, rue Louis Rech | L-3555 Dudelange T : (+352) 28 100 556 | F : (+352) 28 100 512 | microbiology@lns.etat.lu | www.lns.lu

		Se	Season 2022/23					
Virus	Positivity Rate in %							
	w01	w02	w03	w04	Trend	w04		
Influenzavirus A	26.2	22.5	43.3	40.6	\uparrow	9.5		
Human rhinovirus	9.8	16.3	10.9	16.0	\rightarrow	29.3		
Adenovirus	1.6	5.8	1.1	7.4	\uparrow	19.0		
Respiratory syncytial virus	6.6	2.3	3.3	6.4	\uparrow	1.7		
Metapneumovirus	1.6	1.2	4.3	3.2	\uparrow	8.6		
SARS-CoV-2	13.1	9.0	6.2	3.1	\checkmark	9.5		
Influenzavirus B	0.0	1.1	1.0	1.6	\rightarrow	12.7		
Parainfluenzavirus	0.0	2.3	0.0	1.1	\rightarrow	0.0		


Table 2. Distribution of respiratory viruses detected within the Sentinel Network previous 4 weeks compared toprevious year.

*Co-detection counted once for each virus detected.



Number of RSV cases detected in different agegroups (N=203) during season 23/24

Figure 3. Displays RSV cases according to different age groups with highest impact among the 0-4 years old.



Number of SARS-CoV-2 variants detected in sentinel network since week 2023/40

Figure 4. Distribution of variants since 2023/40 within sentinel network * All displayed variants include descendant lineages, except those specified on the legend. For example, XBB does not include XBB.1.5, XBB.1.16, EG.5 and XBB.1.9

References

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 29 January 2024, from https://www.ecdc.europa.eu/en/covid-19/variants-concern

European Centre for Disease Prevention and Control. Communicable Disease Threats Report Week https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-21 -27 January 2024-week-4

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 29 January 2024, from https://www.gisaid.org

GitHub - cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. (2023). Retrieved 29 January 2024, from https://github.com/cov-lineages/pangolin

Hadfield J., Megill C., Bell S., Huddleston J., Potter B., Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. Bioinformatics, 34(23), 4121-4123. doi: 10.1093/bioinformatics/bty407

Rambaut A., Holmes E., O'Toole Á., Hill V., McCrone J., Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology, 5(11), 1403-1407. doi: 10.1038/s41564-020-0770-5

World Health Organization. Tracking sars-COV-2 variants Retrieved 29 January 2024, from https://www.who.int/activities/tracking-SARS-CoV-2-variants